| |
Inform important business questions and address new analytical use cases in a rapidly changing patient landscape. Get easy access to a diverse and expanding list of emerging and innovative healthcare data partners. Click here for more information. .png)
|
|
|
Tuesday, April 11, 2023 | 12pm ET / 9am PT In this webinar we will guide you along the scientific data journey where you can discover smart ways to get from raw data to insights and how to achieve an automated, interconnected lab with data liquidity across the organization. Register now. 
|
|
| By Fraiser Kansteiner The Biden Administration’s solicitor general, Elizabeth Prelogar, told the Supreme Court that the case is a “suitable vehicle” to address the argument over skinny labels. |
|
|
|
By Annalee Armstrong Eli Lilly’s up-and-coming Alzheimer’s disease treatment remternetug seems to have resulted in an early, dose-dependent reduction in amyloid plaques during a small phase 1 study. But the therapy also ran into a common side effect for the anti-amyloid monoclonal antibody class—although it is early days for the data. |
By Max Bayer The lab of gene editing pioneer David Liu is out with new research touting the potential of base editing to bolster existing spinal muscular atrophy treatments. The researchers said that when combined with an FDA-approved treatment, therapeutic benefits were significantly extended. |
By Angus Liu,Eric Sagonowsky After already spending billions to defend itself against claims its talc products cause cancer, J&J is moving to end the litigation altogether. But lawyers for some plaintiffs have said the offer is "woefully inadequate." |
|
Showcase individuals, teams, and companies leading the way in adopting innovative tools & beyond-the-pill technologies to push campaigns to the next level. Deadline is May 4th. Enter today! 
|
|
By Annalee Armstrong A new community-generated data resource from Pillar VC, the Founder-led Biotech Summit and compensation analysis firm Pave seeks to take the guesswork out of the process by summarizing salary ranges from 90 companies. |
By Conor Hale Already popular with the parents of newborns, the makers of the Snoo motorized bassinet hope it will become the favored choice among hospitals and, perhaps one day, insurance providers. |
By Fraiser Kansteiner While Merck & Co.’s Seagen buyout wasn't fated to be, the companies’ clinical courtship in cancer has blossomed into a swift approval at the FDA. |
By Annalee Armstrong Sumitomo Pharma is doing a little bit of spring cleaning to bring a handful of biopharma units under one consolidated company to be named Sumitomo Pharma America. |
By Angus Liu In the latest example of biopharma's ongoing investment in cell and gene therapy production, Sartorius has agreed to acquire French viral vector expert Polyplus for $2.6 billion. But there are some signs of cooling in the field. |
By Nick Paul Taylor Drugmakers are failing to provide Europeans with the information to understand the benefits and harms of oncology medicines. That is the headline finding of a paper published in The BMJ, which found patient information leaflets routinely lack details that could support informed decision making. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss how this year is chock-full of blockbuster drugs headed for the patent cliff, besides the well-known patent cliff for AbbVie's Humira. We also cover Johnson & Johnson's talc settlement offer and more of this week's top headlines. |
|
|---|
|
|
Whitepaper Accelerated approval pathways create an additional layer of complexity in the chaotic oncology marketplace, leaving manufacturers of all sizes seeking a new commercialization model for launch success. Sponsored by: EVERSANA |
Whitepaper The preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process Sponsored by: ReachBio | The Cell Biology Experts™ |
Whitepaper We’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing? Sponsored By: CCC |
Research The current real-world safety reporting process is too burdensome for most HCPs – how can technology help? Sponsored by: Veradigm |
Whitepaper How advanced medicines commercial readiness differs and the resources needed to maximize potential. Sponsored by: Herspiegel Consulting |
Whitepaper This paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| May 1-3, 2023 | Jersey City, NJ |
|
|
| |
|
